Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FM vs FC Conditioning for Allogeneic HSCT in Metastatic RCC
NCT00429026Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2004
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of melphalan, cyclophosphamide in renal cell carcinoma (RCC), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2004; status: terminated.
02
Drugs
melphalancyclophosphamide
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00429026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00429026.